Mitigating Prior Authorization Burdens: Insights from Reference Committee G
93% of physicians report delays in patient care due to prior authorization processes.
- Publisher
- American Medical Association
- Length
- 136 pages
- File
- 0 B PDF
Why this matters
Ninety-three percent of physicians report delays in patient care due to prior authorization.
Executive summary
- Ninety-three percent of physicians report delays in patient care due to prior authorization.
- Eighty-two percent of patients abandon treatment because of prior authorization barriers.
- The American Medical Association (AMA) is developing a database to analyze prior authorization impacts.
- Legal action against insurers is being considered based on prior authorization data.
- Prior authorization processes contribute to physician burnout.
AI research brief
93% of physicians report delays in patient care due to prior authorization processes.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- Regulatory affairs teams
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 136-page PDF
Free · 0 B · Instant access after email
Reference Committee G addresses the excessive burdens of prior authorization, noting that 93% of physicians report delays in patient care due to prior authorization, and 82% of patients abandon treatment because of these barriers.
Key Takeaways
- Ninety-three percent of physicians report delays in patient care due to prior authorization.
- Eighty-two percent of patients abandon treatment because of prior authorization barriers.
- The American Medical Association (AMA) is developing a database to analyze prior authorization impacts.
- Legal action against insurers is being considered based on prior authorization data.
- Prior authorization processes contribute to physician burnout.
What is the focus of this document?
The document addresses the excessive burdens of prior authorization processes on healthcare providers and patients, outlining the AMA's policy responses and proposed actions.
Why does this matter for pharma teams?
Understanding the challenges posed by prior authorization is crucial for pharma teams to navigate regulatory environments and advocate for policies that facilitate patient access to medications.
Frequently Asked Questions
What is prior authorization?
Prior authorization is a process used by health insurers requiring physicians to receive approval from plans before certain prescribed medications, procedures, or treatments can be provided to patients.
What is the AMA's role in addressing prior authorization issues?
The AMA is actively generating a prior authorization database, strengthening public awareness campaigns, and considering legal action against insurance companies based on prior authorization data.
What are the consequences of prior authorization delays?
Delays in prior authorization can lead to patients abandoning treatment, serious adverse events, and increased physician burnout.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related intelligence
Digital Transformation in Pharma CRM: Enhancing HCP Engagement
Digital channels are increasingly preferred by HCPs over traditional in-person interactions.
RYBREVANT® Access and Reimbursement Guide Overview
RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 in…
Guidance on Developing Treatments for Stimulant Use Disorders
FDA has not yet approved any medications for stimulant use disorders.